ArticleClinical endocrinology2022
Male pituitary-gonadal axis dysfunction in post-acute COVID-19 syndrome-Prevalence and associated factors: A Mediterranean case series.
Article in Clinical endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Sex Differences in Long COVID.JAMA network open · 2025Article
- Exploring the Complexities of Long COVID.Viruses · 2024Review
- Impact of COVID-19 infections and vaccination on menstrual cycle symptoms in the south of Jordan: a cross-sectional study.The Journal of the Egyptian Public Health Association · 2024Article
- A prospective study on endocrine function in patients with long-COVID symptoms.Hormones (Athens, Greece) · 2024Observational
- The Growing Understanding of the Pituitary Implication in the Pathogenesis of Long COVID-19 Syndrome: A Narrative Review.Advances in respiratory medicine · 2024Review
- Use of testosterone replacement therapy to treat long-COVID-related hypogonadism.Endocrinology, diabetes & metabolism case reports · 2024Article
- A Scientometric Evaluation of COVID-19 and Male Reproductive Research.Clinics and practice · 2023Article
- The Complex Interplay between Serum Testosterone and the Clinical Course of Coronavirus Disease 19 Pandemic: A Systematic Review of Clinical and Preclinical Evidence.The world journal of men's health · 2023Review
- SARS-CoV-2, fertility and assisted reproduction.Human reproduction update · 2023Review
- Post-COVID-19 Syndrome Mechanisms, Prevention and Management.International journal of preventive medicine · 2023Review
- Pathophysiology of Post-COVID syndromes: a new perspective.Virology journal · 2022Review
- Higher premorbid serum testosterone predicts COVID-19-related mortality risk in men.European journal of endocrinology · 2022Article
- [Androgenic status in men during COVID-19].Problemy endokrinologii · 2022Article
- Male pituitary-gonadal axis dysfunction in post-acute COVID-19 syndrome-Prevalence and associated factors: A Mediterranean case series.Clinical endocrinology · 2022Article
- [Post-COVID syndrome. The never ending challenge].Medicina clinica · 2022Article
- Post-COVID-19 menstrual abnormalities and infertility: Repercussions of the pandemic.Journal of education and health promotion · 2022Review
- Impact of COVID-19 on the Endocrine System: A Mini-review.Endocrinology · 2022Article
- Abnormalities of Endocrine Function Tests in COVID-19-Recovered Individuals.Indian journal of endocrinology and metabolismArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveSevere acute respiratory syndrome coronavirus 2 through angiotensin-converting enzyme 2 receptor can harm testes function. The objectives were to analyse the prevalence of low serum testosterone (LT) and impaired fertility potential (Leydig and Sertoli cells dysfunction, respectively) in coronavirus disease 2019 (COVID-19) male survivors and to evaluate acute infection-related associated factors. Also, we explore its association with post-acute COVID-19 syndrome (PCS) and quality of life (QOL). MATERIALS AND
methodsMale adults recovered from polymerase chain reaction-confirmed COVID-19 were offered a structured evaluation 8-12 weeks after recovery. The main outcome measure(s) were as follows: LT, defined as total testosterone (TT) < 2 ng/ml or if TT levels 2-4 ng/ml as calculated free testosterone < 6.36 ng/dl; Sertoli cell dysfunction was defined as inhibin-B < 89 pg/ml. Secondary outcome-associated factors were analysed by multiple logistic regression (odds ratio; 95% confidence interval [CI]). QOL was evaluated by SF-36 v.2.
resultsOne hundred and forty-three patients were evaluated at a median (interquartile range) of 77 days (72-83) after disease onset; 72% of them recovered from severe pneumonia. LT was detected in 41 patients (28.7%; 95% CI: 21.8-36.5). Low levels of inhibin-B were detected in 25 patients (18.1%; 95% CI: 12.5-25.3). After multivariate adjustment, obesity and hypokalaemia were associated with LT, whereas age more than 65 was an independent predictor of Sertoli cell dysfunction. LT or Sertoli cell dysfunction was not associated with PCS. Patients with LT had a lower score in four domains of QOL.
conclusionsPrevalence of male LT and impaired fertility potential in COVID-19 survivors is high in the medium term. Traditional risk factors and severity markers for COVID-19 could be predictive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.